neximmune.com - NEXI Income before deduction of interest, taxes and amortization
NexImmune, Inc. (NEXI) is developing T-cell activation methods amidst intense patent battles and high R&D costs. The annual EBITDA figure allows for real-time tracking of cash flow, while indicates the level of this metric. The project relies on the innovative AIM platform in US laboratories, while ensuring the seamless delivery of critical reagents.
NexImmune - analytical breakdowns and key metrics (NEXI)
- market value and analyst target forecast:
- issuer market value details:
- book capitalization information:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
NEXI - Net Income|Future Net Profit NexImmune, Inc.|NEXI - P/E Multiple|Future Price to Earnings Multiple neximmune.com|NEXI - PEG Multiple|Company Value to EBITDA NexImmune|NEXI - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year NexImmune|NEXI - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth neximmune.com|NEXI - Earnings per share growth in current year|Net earnings per share change forecast for next year NexImmune, Inc.
Analysis of all company metrics:NexImmune Corporation - NEXI
NexImmune, Inc. (NEXI) occupies a promising niche within the underserved T-cell cancer immunotherapy segment, where high clinical demand drives scaling potential. By analyzing the EBITDA chart, an investor assesses the net cash flow from core operations without the impact of debt service; steady growth in this metric confirms the business's fundamental stability, whereas stagnation signals risks of asset impairment.
Competitors of NexImmune, Inc. (NEXI)
NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|Operating profit before deduction of amortization xencor.com XNCR|Compass Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Group Inc REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (Innate Pharma S.A) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Compugen (CGEN)|Operating profit before deduction of amortization IOBT|STRO - Operating profit before depreciation charges|Operating profit before deduction of amortization INKT (MiNK)|Company profit before taxes, interest and amortization HOWL|Operating profit EBITDA IMMX (Immix Biopharma)|Income before deduction of interest, taxes and amortization ALXO|Cue Biopharma, Inc. - Operating profit EBITDA|Profit before interest, taxes and amortization PDS Biotechnology|sonnetbio.com (SONN) - Profit before payment of interest, taxes and amortization|MAIA Bio - Income before deduction of interest, taxes and amortization|LIMN (Liminatus Pharma) - Operating profit EBITDA|Operating profit EBITDA Lava Tx|Profit before payment of interest, taxes and amortization NextCure (NXTC)|LPTX: Profit before deduction of interest, taxes, depreciation and amortization|Intensity Therapeutics, Inc. - Operating profit before deduction of amortization|Sensei Biotherapeutics Inc (SNSE) - Profit before interest, taxes and amortization|TOVX - Profit before payment of interest, taxes and amortization|GRTS (Gritstone bio, Inc.) - Operating profit before amortization|KA: Operating profit EBITDA|Profit before interest, taxes and amortization Turnstone Biologics Corp. (TSBX)|Operating profit before deduction of amortization VCNX|Operating profit before amortization HARP (Harpoon Therapeutics Corp)
